Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Ligand Binding Sites

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...

Ligand Binding Sites

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Ligand Binding and Linkage

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Conserved Binding Sites

Conserved Binding Sites

Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally analyses the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Augmented BindingNet dataset for enhanced ligand binding pose predictions using deep learning.

npj drug discovery·2026

Same author

A Nanoconfined, Hydrogel-Partitioned LAMP Platform for Rapid, Extraction-Free Quantification of <i>Mycoplasma pneumoniae</i>.

ACS infectious diseases·2026

Same author

Screening and Quality Evaluation of Submerged Culture Media Formulations for <i>Pleurotus pulmonarius</i>.

Journal of fungi (Basel, Switzerland)·2026

Same author

Evaluation of <i>Corcyra cephalonica</i> as an Alternative Host for <i>Meteorus pulchricornis</i>.

Insects·2026

Same author

Neoplasm Adverse Events Associated With Anti-Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study.

Cancer medicine·2026

Same author

High-Throughput BLI for One-Step Anti-<i>Pseudomonas plecoglossicida</i> IgM Detection in <i>Larimichthys crocea</i> Serum.

International journal of molecular sciences·2026

Search research articles

Related Experiment Video

Updated: May 21, 2026

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

Identifying multiple-target ligands via computational chemogenomics approaches.

Shiming Peng¹, Xingyu Lin, Zongru Guo

¹College of Biological Sciences, China Agricultural University, Beijing 100094, China.

Current Topics in Medicinal Chemistry

|June 14, 2012

Summary

Computational chemogenomics predicts drug-target interactions for multi-target drug design. This approach aids in developing effective treatments for complex diseases by optimizing drug binding profiles.

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Related Experiment Videos

Last Updated: May 21, 2026

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Area of Science:

Computational chemistry
Drug discovery
Pharmacology

Background:

Target-based drug discovery is costly and inefficient, especially for complex diseases like cancer.
Single-target drugs often show limited efficacy in treating multifactorial conditions.
Developing drugs that interact with multiple targets presents a significant challenge.

Purpose of the Study:

To review computational chemogenomics approaches for predicting ligand-target interactions.
To highlight methods for designing drugs with desired binding spectrums and eliminating unwanted activities.
To emphasize the importance of predicting ligand binding profiles for multi-target drug design.

Main Methods:

Structure-based methods (e.g., binding site mapping, inverse molecular docking) utilize known target structures.
Ligand-based approaches (e.g., chemical similarity, pharmacophore searching) use active compound data.
These methods predict potential interactions between small molecules and biological targets.

Main Results:

Computational chemogenomics enables prediction of comprehensive ligand-target interaction profiles.
Structure-based and ligand-based methods offer complementary strategies for drug design.
Information derived aids in engineering desirable binding spectra and eliminating off-target effects.

Conclusions:

Computational chemogenomics is crucial for rational multi-target drug design.
Predicting ligand binding profiles is an essential first step in this process.
These computational approaches can significantly improve the efficiency and success rate of drug innovation.